Oncolytics Biotech Appoints Jared Kelly CEO After $2B Deal Success

Oncolytics Biotech Inc. has appointed Jared Kelly as its new Chief Executive Officer and a member of its Board of Directors. Kelly brings significant experience in transformative biotech deals, most notably orchestrating the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Under his leadership, Oncolytics aims to advance the clinical development of its lead drug, pelareorep, an immunotherapeutic agent that has shown promising results with over a 60% objective response rate in metastatic pancreatic cancer trials and has received FDA Fast Track designation for multiple indications. Kelly’s compensation package includes stock options and performance-based incentives designed to align with long-term shareholder value and the expansion of pelareorep’s clinical and commercial footprint. His background includes advising biotech companies on mergers and acquisitions, and he holds advanced law degrees from Georgetown University. The company’s stock has remained relatively stable following the announcement, reflecting investor interest in its promising immunotherapy programs.